Objective: To examine whether prenatal opioid use disorder (OUD) diagnosis is associated with the risk of congenital anomalies (CAs) in offspring.
Methods: We conducted a population-based study of mother-newborn dyads comprising. 4143 761 births delivered in Canada from 2006 to 2021. We used robust Poisson regression to examine the association between prenatal OUD diagnosis and risk of non-chromosomal CAs, adjusted for maternal age, parity, multiple gestation, co-morbidities (including mental health disorders, chronic illnesses and other substance use disorders), and infant sex.
Results: We identified a total of 21, 638 births to persons who were diagnosed with prenatal OUD and 65, 992 (159.3 per 10,000) newborns with CAs. The overall risk of CAs was 2.3 times higher in infants born to birthing persons with a diagnosis of OUD (95% CI 2.2, 2.5). Compared to those without OUD diagnoses, births to persons with a diagnosis of OUD had a higher risk of specific types of congenital microcephaly (aRR 5.2, 95% CI 4.1, 6.6), cleft palate (RR 4.8, 95% CI 3.7, 6.1), pulmonary valve atresia with intact ventricular septum (aRR 2.7, 95% CI 1.1, 6.7), and atrial septal defect (aRR 3.1, 95% CI 2.8, 3.5), among others. In particular, infants born to those with an OUD diagnosis had a 1.8 (95% CI 1.4, 2.3)-fold increased risk of having severe congenital heart disease.
Conclusion: Our findings suggest an association between prenatal OUD diagnosis and certain CAs in the offspring. Future research is necessary to better understand the role of socio-demographic factors on these associations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841020 | PMC |
| http://dx.doi.org/10.1002/bdr2.2456 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Medicaid Enrolment Death Data to State-Wide Death Records in Maine.
J Eval Clin Pract
March 2025
Maine Department of Health and Human Services, Office of MaineCare Services, Augusta, Maine.
Rationale: Death data available in Medicaid enrolment files may be incomplete and lack cause of death information. We sought to compare Medicaid enrolment death data to state-wide death records in Maine.
Aims And Objectives: (1) To compare the date of death of Medicaid enrollees in Maine according to the Medicaid enrolment data to the date of death obtained through an ongoing quarterly death certificate-Medicaid linkage for 2016-2023; and (2) using the death certificate-Medicaid linkage data, to perform an analysis of the risk of drug overdose death in 2023 by opioid use disorder (OUD) status in 2023, as part of monitoring activities required for one of Maine's new approaches to delivering Medicaid services.
Risk of Oral Health Problems in Adults with Opioid Use Disorder Treated with Transmucosal Buprenorphine.
J Addict Med
March 2025
From the Departments of Family and Community Medicine and Public Health Science, College of Medicine, Pennsylvania State University, Hershey, PA (W-JT); Department of Family and Community Medicine, College of Medicine, Pennsylvania State University, Hershey, PA (KTC, JS); College of Medicine, Pennsylvania State University, Hershey, PA (EJ); and Departments of Family and Community Medicine, Anesthesiology and Perioperative Medicine, and Public Health Science, Pennsylvania State University, Hershey, PA (AEZ).
Objectives: In early 2022, based on limited case-report evidence, the US Food and Drug Administration warned about possible oral health problems associated with transmucosal (sublingual, buccal) buprenorphine formulations commonly used to treat opioid use disorder (OUD). The purpose of this study was to assess the risk of adverse oral health outcomes among adults prescribed transmucosal buprenorphine for OUD.
Methods: This retrospective cohort study utilizing TriNetX claims data consisted of adults diagnosed with OUD in 2002-2019, and who either filled ≥3 transmucosal buprenorphine prescriptions within any 6-month period (buprenorphine cohort) or did not fill any buprenorphine prescriptions (control cohort).
Objectives: People with childbearing potential and opioid use disorder (OUD) have high rates of unintended pregnancies. Addiction medicine providers occupy an important role in diagnosing and counseling those who become pregnant; however, no guidelines exist to facilitate these conversations. We sought to explore participant experiences with pregnancy options counseling while in opioid use disorder treatment clinics.
View Article and Find Full Text PDFAssessing inequities in buprenorphine treatment across the care cascade.
Drug Alcohol Depend
February 2025
Department of Pediatrics, Boston Medical Center, USA; Department of Pediatrics, Boston Medical Center, USA.
Objective: Describe buprenorphine treatment gaps across the care cascade by race, ethnicity, age, sex and key clinical characteristics.
Design: Observational cohort study of new opioid use disorder (OUD) treatment episodes, 1/1/15-12/31/21 PARTICIPANTS: Individuals 16-89 years at Boston Medical Center and affiliated Boston-area clinics with OUD or buprenorphine prescription following 90-day washout MAIN OUTCOMES AND MEASURES: Buprenorphine initiation (by 14d), engagement (second prescription by 34d), and retention (continuous buprenorphine through 180d without >14d gap). Covariates: sex, race and ethnicity, age, past 12-month buprenorphine, past 12-month overdose, co-occurring substance use disorder (SUD) and psychiatric diagnosis.
Induced craving frequently leads to relapse in patients with a history of opioid use disorder (OUD). Quantifying the physiological manifestations of craving can enable caregivers of patients with OUD to continuously monitor craving and thus help inform treatment plans. Heart rate variability (HRV) is a promising candidate to capture the trends in such manifestations due to the ease of measuring changes in heartbeat intervals using the electrocardiogram.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!